View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	Apr. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Trading Symbol	CHRS
Entity Registrant Name	Coherus BioSciences, Inc.
Entity Central Index Key	0001512762
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		39,141,521

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 179,558	$ 158,226
Restricted cash	60	60
Receivables from collaboration and license agreement	1,195	1,560
Prepaid assets (includes related parties of $6,891 and $10,901 as of March 31, 2016 and December 31, 2015, respectively)	25,985	34,743
Other assets	4,785	2,797
Total current assets	211,583	197,386
Property and equipment, net	10,296	10,504
Intangible assets	2,620	2,620
Goodwill	943	943
Restricted cash, non-current	785	785
Other assets, non-current	9	146
Total assets	226,236	212,384
Current liabilities:
Accounts payable	17,904	25,948
Accounts payable - related parties	3,494	3,548
Accrued liabilities (includes related parties of $6,256 and $6,122 as of March 31, 2016 and December 31, 2015, respectively)	19,279	24,133
Advance payments under license agreement	970	1,330
Deferred revenue	49,633	49,621
Contingent consideration	1,435	1,245
Other liabilities	205	193
Total current liabilities	92,920	106,018
Deferred revenue, non-current	32,973	45,338
Convertible notes	74,492
Convertible notes - related parties	24,831
Contingent liability to collaborator	66,255	66,255
Other liabilities, non-current	1,643	1,702
Total liabilities	293,114	219,313
Commitments and contingencies (Note 7)
Stockholders’ deficit:
Preferred stock
Common stock	4	4
Additional paid-in capital	409,812	404,175
Accumulated other comprehensive loss	(449)	(401)
Accumulated deficit	(475,373)	(409,985)
Total Coherus stockholders' deficit	(66,006)	(6,207)
Non-controlling interest	(872)	(722)
Total stockholders' deficit	(66,878)	(6,929)
Total liabilities and stockholders’ deficit	$ 226,236	$ 212,384

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Prepaid assets	$ 25,985	$ 34,743
Accrued liabilities, related parties	6,256	6,122
Clinical Material Manufacturing And Other Related Parties
Prepaid assets	$ 6,891	$ 10,901

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue:
Collaboration and license revenue	$ 12,359	$ 5,810
Total revenue	12,359	5,810
Operating expenses:
Research and development (includes related party of $13,262 and $11,481 for the three months ended March 31, 2016 and 2015, respectively)	65,313	36,467
General and administrative (includes related party of $0 and $66 for the three months ended March 31, 2016 and 2015, respectively)	11,398	6,091
Total operating expenses	76,711	42,558
Loss from operations	(64,352)	(36,748)
Interest expense (includes related party of $209 and $0 for the three months ended March 31, 2016 and 2015, respectively)	(837)
Other expense, net	(349)	(4,091)
Net loss	(65,538)	(40,839)
Net loss attributable to non-controlling interest	150	114
Net loss attributable to Coherus	$ (65,388)	$ (40,725)
Net loss per share attributable to Coherus, basic and diluted	$ (1.67)	$ (1.22)
Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted	39,095,975	33,377,298

Condensed Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Research and development from transactions with related party	$ 13,262	$ 11,481
General and administrative expenses from transactions with related party	0	66
Interest expense from transactions with related party	$ 209	$ 0

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (65,538)	$ (40,839)
Other comprehensive loss:
Foreign currency translation adjustments, net of tax	(48)	(123)
Comprehensive loss	(65,586)	(40,962)
Comprehensive loss attributable to non-controlling interest	150	114
Comprehensive loss attributable to Coherus	$ (65,436)	$ (40,848)

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities
Net loss	$ (65,538)	$ (40,839)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	717	232
Remeasurement of contingent consideration	190	4,214
Non-cash interest expense (income) from amortization of debt discount (receivable)	107	(22)
Provision for other receivables	(1,300)
Stock-based compensation expense	5,318	2,182
Changes in operating assets and liabilities:
Receivables from collaboration and license agreement	365	402
Prepaid assets	8,776
Other assets	(668)	389
Other assets, non-current	86	(769)
Accounts payable	(6,797)	3,027
Accounts payable - related parties	(54)	1,703
Accrued and other liabilities	(4,735)	1,944
Deferred revenue	(12,365)	(5,512)
Advance payments under license agreements	(360)
Other liabilities, non-current	(58)	(13)
Net cash used in operating activities	(76,316)	(33,062)
Investing activities
Purchases of property and equipment	(2,148)	(1,313)
Net cash used in investing activities	(2,148)	(1,313)
Financing activities
Proceeds from issuance of convertible notes	75,000
Proceeds from issuance of convertible notes - related parties	25,000
Convertible notes issuance costs	(455)
Proceeds from issuance of common stock upon exercise of stock options	298	168
Net cash provided by (used in) financing activities	99,843	(729)
Effect of exchange rate changes in cash and cash equivalents	(47)	(152)
Net increase in cash and cash equivalents	21,332	(35,256)
Cash and cash equivalents at beginning of period	158,226	150,392
Cash and cash equivalents at end of period	$ 179,558	115,136
Initial Public Offering
Financing activities
Payments of offering costs		(855)
Follow-On Public Offering
Financing activities
Payments of offering costs		$ (42)

Organization and Operations

3 Months Ended

Mar. 31, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Organization and Operations

1.	Organization and Operations

Description of the Business

Coherus BioSciences, Inc. (the “Company”, “Coherus”, “we”, “our” or “us”) is a late-stage clinical biologics platform company, focused on the global biosimilar market. The Company’s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. The Company operates in one segment.

The Company’s clinical stage pipeline consists of a long-acting form of granulocyte colony-stimulating factor (“G-CSF”), and two anti-inflammatory agents targeting tumor necrosis factor (“TNF”):

The Company’s long-acting G-CSF product candidate, CHS-1701, is being developed as a pegfilgrastim (Neulasta) biosimilar. In October 2015, the Company completed a pivotal pharmacokinetic (PK) and pharmacodynamics (PD) study for CHS-1701 in the United States (U.S.). Although it did not meet the PK AUC bioequivalence endpoint due to low, anomalous PK profile in the first period Neulasta group, this study will be included in the planned filing of a biologics license application (BLA) in the U.S. as it met all the other co-primary endpoints, including the PD endpoints. In February 2016, an immunogenicity study in healthy volunteers pursuant to this BLA met its primary endpoints and the Company initiated a follow-on PK/PD study, which is expected to read-out late in the first half of 2016. The Company expects to file a BLA in the U.S. directly thereafter.

The Company’s most clinically advanced anti-TNF product candidate, CHS-0214, is being developed as an etanercept (Enbrel) biosimilar that the Company has partnered with Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH, (collectively “Baxalta”) and Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) to develop and commercialize in key markets outside of the U.S. The Company completed two Phase 3 clinical trials with CHS-0214 in rheumatoid arthritis and psoriasis, which met their primary clinical endpoints in November 2015 and January 2016, respectively. The Company expects that results from these trials, combined with data from its Phase 1 studies, will support the expected filing of a marketing application in Europe and Japan in 2016. The Company has retained the development and commercial rights to this product in the U.S. However, the therapeutic protein in etanercept is subject to certain originator-controlled U.S. patents expiring in 2028 and 2029. Assuming these patents are valid and enforceable, and that the Company would be unable to obtain a license to them, the Company does not expect to commercialize CHS-0214 in the U.S. prior to their expiration.

The Company’s second anti-TNF product candidate, CHS-1420, is being developed as an adalimumab (Humira) biosimilar. This product successfully completed a pivotal Phase 1 PK study in August 2014 by meeting the primary PK bioequivalence endpoint. The Company initiated a Phase 3 study in psoriasis in August 2015 to support the planned filing of a marketing application in the U.S. in 2016 and the E.U. in 2017. The Company initiated a bridging PK study comparing the Phase 3 CHS-1420 material to U.S. manufactured adalimumab (Humira) during the first quarter of 2016.

Need to Raise Additional Capital

As of March 31, 2016, the Company had an accumulated deficit of $475.4 million and cash and cash equivalents of $179.6 million. In February 2016, we issued and sold $100.0 million aggregate principal amount of 8.2% senior convertible notes due March 31, 2022 (see Note 6). The Company believes that its current available cash and cash equivalents, together with funding it expects to receive under its license agreements with Daiichi Sankyo and Baxalta, and additional projected license agreements, will be sufficient to fund its planned expenditures under its 2016 budget and meet the Company’s obligations through at least the next twelve months. The Company will need to raise additional funds in the future, however there can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be favorable. If the Company is unable to obtain adequate financing when needed, it may have to delay, reduce the scope of or suspend one or more of its clinical trials, research and development programs or commercialization efforts.

Basis of Presentation and Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

2.	Basis of Presentation and Summary of Significant Accounting Policies

Unaudited Condensed Consolidated Financial Statements

The accompanying condensed consolidated financial statements include the accounts of Coherus and its wholly owned subsidiaries as of March 31, 2016: Coherus Intermediate Corp, Coherus Oncology, Inc., InteKrin Therapeutics Inc. (“InteKrin”), and InteKrin’s 82.5% majority owned subsidiary of InteKrin Russia. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company’s operations and cash flows for interim periods in accordance with U.S. GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.

The accompanying condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on February 29, 2016.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, valuation of deferred tax assets, impairment of goodwill and long-lived assets, the valuation of acquired intangible assets, clinical trial accruals, revenue recognition period, contingent consideration, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

Foreign Currency

The functional currency of InteKrin Russia, which the Company acquired in February 2014, is the Russian Ruble. Accordingly, the financial statements of this subsidiary are translated into U.S. dollars using appropriate exchange rates. Unrealized gains or losses on translation are recognized in accumulated other comprehensive loss in the condensed consolidated balance sheet.

The foreign exchange gains and losses recorded in other expense, net in the condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015, were a net loss of $264,000 and a net gain of $91,000, respectively.

Segment Reporting and Customer Concentration

The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing biosimilar products, and, as part of the InteKrin acquisition, small molecules. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Long-lived assets are primarily maintained in the United States of America.

The following table summarizes revenue by geographic region (in thousands):

	Three Months Ended
	March 31,
	2016		2015
United States	$	12,005	$	5,313
Rest of world		354		497
Total revenue	$	12,359	$	5,810

Customers whose collaboration and license revenue accounted for 10% or more of total revenues were as follows:

	Three Months Ended
	March 31,
	2016			2015
Baxalta		97	%		91	%

Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists; transfer of technology has been completed, services have been performed or products have been delivered; the fee is fixed and determinable; and collection is reasonably assured.

For revenue agreements with multiple elements, the Company identifies the deliverables included within the agreement and evaluates which deliverables may represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. Deliverables under the arrangement are a separate unit of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item and delivery or performance of the undelivered items are considered probable and substantially within the Company’s control.

The Company determines how to allocate arrangement consideration to identified units of accounting based on the selling price hierarchy provided under the relevant guidance. The selling price used for each unit of accounting is based on vendor-specific objective evidence, if available, third party evidence if vendor-specific objective evidence is not available or estimated selling price if neither vendor-specific nor third-party evidence is available. Management may be required to exercise considerable judgment in determining whether a deliverable is a separate unit of accounting and in estimating the selling prices of identified units of accounting under its agreements.

Upfront payments received in connection with licenses of the Company’s technology rights are deferred if facts and circumstances dictate that the license does not have stand-alone value. Such payments are recognized as license revenue over the estimated period of performance that is generally consistent with the terms of the research and development obligations contained in the specific collaboration and license agreement. The Company regularly reviews the estimated period of performance based on the progress made under each arrangement. Amounts received as funding of research and development activities are recognized as revenue if the collaboration arrangement involves the sale of the Company’s research or development services. However, such funding is recognized as a reduction in research and development expense when the Company engages in a research and development project jointly with another entity, with both entities participating in project activities and sharing costs and potential benefits of the arrangement.

Payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved, assuming all other revenue recognition criteria are met. A milestone is defined as an event that can only be achieved based on the Company’s performance where there is substantive uncertainty about whether the event will be achieved at the inception of the arrangement. Events that are contingent only on the passage of time or only on counterparty performance are not considered milestones under accounting guidance. The Company’s evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the Company’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the Company’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.

Other contingent payments in which a portion of the payment is refundable or adjusts based on future performance or non-performance (e.g., through a penalty or claw-back provision) are not considered to relate solely to the Company’s past performance, and therefore, not considered substantive. Non-substantive contingent payments are classified as deferred revenue if they are ultimately expected to result in revenue recognition. The Company recognizes non-substantive contingent payments over the remaining estimated period of performance once the specific objective is achieved. Any portion of the non-substantive contingent payments which may be required to be refunded to the collaborator are not included in deferred revenue and instead are reflected as contingent liability to collaborator on the condensed consolidated balance sheets.

Contingent payments associated with the achievement of specific objectives in certain contracts that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are recognized as revenue upon achievement of the objective, as long as there are no undelivered elements remaining and no continuing performance obligations by the Company, assuming all other revenue recognition criteria are met.

Revenue from a government contract is recognized in the period during which the related costs are incurred and the related services are rendered, provided that the funds received are not refundable and applicable conditions under the government contract have been met. Funds received in advance are recorded as deferred revenue.

Comprehensive Loss

Comprehensive loss is composed of two components: net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity, but are excluded from net loss. The Company’s other comprehensive loss includes foreign currency translation adjustments for the three months ended March 31, 2016 and 2015.

Net Loss per Share Attributable to Coherus

Basic net loss per share attributable to Coherus is calculated by dividing the net loss attributable to Coherus by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common shares. Diluted net loss per share is computed by dividing the net loss per share by the weighted average number of common shares outstanding for the period plus any dilutive potential common shares outstanding for the period determined using the treasury stock method for options to purchase common stock and using the if-converted method for the convertible notes. Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Coherus is the same as diluted net loss per share attributable to Coherus as the inclusion of all potential dilutive common shares would have been anti-dilutive for all periods presented. Shares of founders’ common stock subject to repurchase are excluded from the calculation of weighted average shares as the vesting of such shares is contingent upon continued services being rendered by such holders.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which converges the FASB and the International Accounting Standards Board standards on revenue recognition. Areas of revenue recognition that will be affected include, but are not limited to, transfer of control, variable consideration, allocation of transfer pricing, licenses, time value of money, contract costs and disclosures. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date (“ASU 2015-14”). Under the amendments in ASU 2015-14, the FASB deferred the effective date of ASU 2014-09 for public business entities to fiscal years beginning after December 15, 2017, including interim reporting periods within that reporting period, with early adoption permitted on the original effective date of fiscal years beginning after December 15, 2016. The Company may adopt the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the method and the impact that the adoption of ASU 2014-09 will have on its consolidated financial statements and related disclosures.

In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU 2014-15 is effective for the Company’s annual reporting period ending December 31, 2016 and all annual and interim reporting periods thereafter, with early adoption permitted. The Company has not elected to early adopt this standard. When adopted, ASU 2014-15 will require management to evaluate whether there is substantial doubt about the Company’s ability to continue as a going concern for at least 12 months from the issuance date of the financial statements and to provide related footnote disclosures.

In January 2016, the FASB issued ASU No. 2016-1, Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-1 makes amendments to the classification and measurement of financial instruments and revises the accounting related to: (1) the classification and measurement of investments in equity securities, and (2) the presentation of certain fair value changes for financial liabilities measured at fair value. In addition, the update also amends certain disclosure requirements associated with the fair value of financial instruments. ASU 2016-1 is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2018, and all annual and interim reporting periods thereafter. Early adoptions of certain amendments within the update are permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-1 will have on its consolidated financial statements and related disclosures.

In February 2016, the FASB issued ASU No. 2016-2, Leases. ASU 2016-2 is aimed at making leasing activities more transparent and comparable, and requires substantially that all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU 2016-2 is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2019, and all annual and interim reporting periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-2 will have on its consolidated financial statements and related disclosures.

In March 2016, the FASB issued ASU No. 2016-9, Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting. ASU 2016-9 simplifies several aspects of the accounting for share-based payment award transactions, including: (1) the income tax consequences, (2) classification of awards as either equity or liabilities, and (3) classification on the statement of cash flows. ASU 2016-9 is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2017, and all annual and interim reporting periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-9 will have on its consolidated financial statements and related disclosures.

In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers, Identifying Performance Obligations and Licensing (ASU 2016-10). The amendments in this update clarify the following two aspects: identifying performance obligations and clarifying the licensing implementation guidance. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09. The Company is currently evaluating the impact that the adoption of ASU 2016-10 will have on its consolidated financial statements and related disclosures.

As of January 1, 2016, the Company adopted ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, that requires debt issuance costs related to a recognized debt liability to be presented in the consolidated balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU 2015-03 requires retrospective application. ASU 2015-03 is limited to the presentation of debt issuance costs applied retrospectively to all prior periods presented in the consolidated financial statements and does not affect the recognition and measurement of debt issuance costs.

The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

Fair Value Measurements

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

3.	Fair Value Measurements

Financial assets and liabilities are recorded at fair value. The carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and other current liabilities approximate their fair value due to their short maturities. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The accounting guidance describes a fair value hierarchy based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable. These levels of inputs are the following:

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s financial instruments consist of Level 1 assets and Level 3 liabilities. Where quoted prices are available in an active market, securities are classified as Level 1. Level 1 assets consist of highly liquid money market funds that are included in cash and cash equivalents, and restricted cash. There were no unrealized gains and losses in the Company’s investments in these money market funds.

In certain cases where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3. Level 3 liabilities consist of the contingent consideration.

Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements are as follows (in thousands):

	Fair Value Measurements
	March 31, 2016
	Total		Level 1		Level 2		Level 3
Assets:
Money market funds	$	179,403	$	179,403	$	—	$	—
Restricted cash (money market funds)		845		845		—		—
Total financial assets	$	180,248	$	180,248	$	—	$	—
Liabilities:
Contingent consideration	$	1,435	$	—	$	—	$	1,435

	Fair Value Measurements
	December 31, 2015
	Total		Level 1		Level 2		Level 3
Assets:
Money market funds	$	157,784	$	157,784	$	—	$	—
Restricted cash (money market funds)		845		845		—		—
Total financial assets	$	158,629	$	158,629	$	—	$	—
Liabilities:
Contingent consideration	$	1,245	$	—	$	—	$	1,245

There were no transfers between Level 1 and Level 3 during the periods presented.

Contingent Consideration

As part of the InteKrin acquisition in February 2014, the Company recognized contingent consideration associated with potential payments to be made to the former InteKrin stockholders upon the achievement of certain events specified in the agreements. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy.

The InteKrin purchase agreement provides for contingent consideration to be paid upon (i) the first dosing of a human subject in the first Phase 2 Clinical Trial for INT-131 ("Earn-Out Payment") and (ii) per a compound transaction agreement as defined in the purchase agreement (the “Compound Transaction Payment”). On March 6, 2015, the Company achieved the first dosing of a human subject in a phase 2 clinical trial for CHS-131 in multiple sclerosis patients, triggering the obligation to settle the first contingent Earn-Out Payment to former InteKrin stockholders. As a result, the Company recognized the additional fair value of the Earn-Out Payment of $4.1 million to other expense, net in the condensed consolidated statement of operations on March 6, 2015 and reclassified the contingent consideration liability balance related to the Earn-Out Payment to equity.

This fair value measurement of the Compound Transaction Payment uses a probability-weighted discounted cash flow approach based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The Compound Transaction analysis applied a 25% risk-adjusted discount rate to measure present value and also captured an additional 7% credit spread for counterparty credit risk given the cash payment. The Company’s management estimates of probability of occurrence and timing were used to formulate an expected cash flow. The value of the consideration is tiered based on the value of a license or similar agreement with a third party and the timing of such agreement. The change in the fair value of the Compound Transaction Payment was recognized in other expense, net within the condensed consolidated statement of operations of $190,000 and $75,000 for the three months ended March 31, 2016 and 2015, respectively.

The following table sets forth a summary of changes in the estimated fair value of the contingent consideration (in thousands):

Balance as of December 31, 2015	$	1,245
Change in fair value of the contingent consideration liability		190
Balance as of March 31, 2016	$	1,435

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Balance Sheet Components

3 Months Ended

Mar. 31, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Balance Sheet Components

4.	Balance Sheet Components

Prepaid Assets

Prepaid assets are as follows (in thousands):

	March 31,		December 31,
	2016		2015
Prepaid clinical, material, manufacturing and other - related parties (see Note 10)	$	6,891	$	10,901
Prepaid clinical, material and manufacturing		16,320		21,191
Prepaid other		2,774		2,651
Prepaid assets	$	25,985	$	34,743

Property and Equipment, Net

Property and equipment, net are as follows (in thousands):

	March 31,			December 31,
	2016			2015
Machinery and equipment	$	8,159		$	7,809
Computer equipment and software		1,374			1,276
Furniture and fixtures		578			596
Leasehold improvements		4,050			4,343
Total property and equipment		14,161			14,024
Accumulated depreciation and amortization		(3,865	)		(3,520	)
Property and equipment, net	$	10,296		$	10,504

Depreciation and amortization expense was $717,000 and $232,000 for the three months ended March 31, 2016 and 2015, respectively.

Accrued Liabilities

Accrued liabilities are as follows (in thousands):

	March 31,		December 31,
	2016		2015
Accrued clinical, manufacturing and other - related parties (See Note 10)	$	6,256	$	6,122
Accrued clinical and manufacturing		8,318		11,681
Accrued compensation		2,664		4,666
Accrued professional and consulting fees		697		446
Accrued other		1,344		1,218
Accrued liabilities	$	19,279	$	24,133

Collaboration and License Agreements

3 Months Ended

Mar. 31, 2016

Collaboration And License Agreements [Abstract]

Collaboration and License Agreements

5.	Collaboration and License Agreements

The Company recognized revenue related to the collaboration and license agreements for the periods presented as follows (in thousands):

	Three Months Ended
	March 31,
	2016		2015
Baxalta	$	12,005	$	5,313
Daiichi Sankyo		354		497
Total collaboration and license revenue	$	12,359	$	5,810

Daiichi Sankyo

In January 2012, the Company entered into a license agreement with Daiichi Sankyo, under which the Company granted certain licenses to Daiichi Sankyo to develop and commercialize biosimilar forms of etanercept and rituximab in Japan, Taiwan, and South Korea, with an option to develop in China. Upon execution of the agreement, Daiichi Sankyo paid a non-refundable, upfront license fee of $10.0 million which was recorded as deferred revenue and is being amortized over the remaining estimated performance period under the agreement using the straight line method.

In June 2013, the Company and Daiichi Sankyo entered into a Memorandum of Understanding No. 1 (the “MOU 1”) in which both parties agreed to cooperate and share costs to conduct a global Phase 1 study of a biosimilar form of etanercept. This program was not originally contemplated in the license agreement. The amounts received from Daiichi Sankyo under the MOU 1 are recognized as a reduction in research and development expense as the Company engages in a research and development project jointly with Daiichi Sankyo, with both parties incurring costs while actively participating in development activities and both parties sharing costs and potential benefits of the arrangement.

In January 2014, the Company and Daiichi Sankyo entered into the Memorandum of Understanding No. 2 (the “MOU 2”) in which both parties agreed to cooperate to conduct a global Phase 3 clinical trial in rheumatoid arthritis and that Daiichi Sankyo will be responsible for a minimum of 20% of the cost of the clinical trial. Also, both parties entered into a clinical supply agreement contemporaneously with the MOU 2 in which the Company will supply finished study drug and study comparator drug for Daiichi Sankyo’s use in the Japanese portion of the product’s clinical trial. Daiichi Sankyo reimburses these research and development costs in quarterly advance payments, for which the Company records as advance payments under license agreement in the condensed consolidated balance sheet. The Company recognizes the advance payments as a reduction in the research and development expense when the research and development activity has been performed.

In June 2015, the Company and Daiichi Sankyo entered into the Memorandum of Understanding No. 3 (the “MOU 3”) in which both parties agreed to cooperate further on a global Phase 3 clinical in rheumatoid arthritis. Under the MOU 3, Daiichi Sankyo will be responsible for a minimum of 20% of the cost of an open label, safety extension study (“OLSES”) in rheumatoid arthritis. The Company also entered into a clinical supply agreement as part of the MOU 3 in which the Company will supply finished study drug and study comparator drug for Daiichi Sankyo’s use in the Japanese portion of the clinical trial. Daiichi Sankyo will pre-pay these research and development costs quarterly, for which the Company records as advance payments under license agreement in the condensed consolidated balance sheet. The Company recognizes the advance payments as a reduction of research and development expense when the research and development activity has been performed.

As of March 31, 2016, $2.4 million of revenue was deferred under all arrangements with Daiichi Sankyo, of which $1.4 million was included in current liabilities and $1.0 million was included in non-current liabilities in the condensed consolidated balance sheet. As of December 31, 2015, $2.8 million of revenue was deferred under all arrangements with Daiichi Sankyo, of which $1.5 million was included in current liabilities and $1.3 million was included in non-current liabilities in the condensed consolidated balance sheet

The Company recognized in its condensed consolidated statements of operations a reduction of research and development expense related to the costs reimbursed by Daiichi Sankyo of $1.1 million and $1.4 million for the three months ended March 31, 2016 and 2015, respectively.

Baxalta

In August 2013, the Company entered into a license agreement with Baxalta (then Baxter International, Inc.), to develop and commercialize an etanercept biosimilar molecule, CHS-0214, worldwide, excluding the United States, Japan, Taiwan, South Korea, China and most of the Caribbean and South American nations. Under the terms of the license agreement, the Company will conduct the development and the regulatory activities, and Baxalta will conduct the commercialization of the etanercept biosimilar product.

In consideration of the exclusive, royalty-bearing license to develop, commercialize and use the etanercept biosimilar product, Baxalta made an upfront payment of $30.0 million to the Company. Additionally, the Company was eligible to receive up to $216.0 million in contingent payments composed of $96.0 million in clinical development payments and up to $120.0 million in regulatory milestone payments. In February 2014, the agreement was amended to increase the payment by $5.3 million. Therefore, the Company became eligible to receive up to $221.3 million in contingent payments comprised of $101.3 million in clinical development payments and up to $120.0 million in regulatory milestone payments. As of December 31, 2014, the Company received a total of $85.3 million in clinical development payments.

The upfront payment of $30.0 million and clinical development payments of up to $101.3 million include $71.3 million of contingent payments that are intended to cover development related expenses incurred by the Company, but which are potentially reimbursable, in part, to Baxalta under certain limited circumstances. Additionally, the amounts that are contingent payments also contain a claw-back feature providing that, in the event that the Company commercializes the etanercept biosimilar molecule in the U.S., 50% of those contingent payments are refundable to Baxalta. Therefore, the Company recorded the portion of the non-substantive contingent payment that contains the claw-back feature as the contingent liability to collaborator on the condensed consolidated balance sheets, and the portion of the non-substantive milestone payments that does not contain the claw-back feature was recorded as deferred revenue and recognized as collaboration and license revenue on a straight-line basis over the remaining estimated performance period. The $120.0 million of regulatory milestone payments which was considered substantive will be recognized as revenue when each specific event is achieved.

In April 2015, the Company and Baxalta, entered into a second amendment (the “Second Amendment”) to the license agreement. Under the terms of the Second Amendment, a revised milestone payment structure totaling $130.0 million replaced certain existing milestone and funding obligations under the license agreement as originally executed. The Second Amendment does not provide for any change in the contracted deliverables set forth in the license agreement. As a result, the original assessment of the standalone value for the deliverables remains unchanged and the deferred revenue previously recorded prior to the Second Amendment continues to be recognized as revenue on a straight-line basis over the remaining expected performance period. Likewise, the contingent liability from the incremental milestones received under the license agreement prior to Second Amendment has not been adjusted.

If the Company commercializes CHS-0214, its etanercept biosimilar product, in the United States, the Company will be required to refund a portion of the milestone payments received from Baxalta as specified in the Second Amendment. A portion of each of the $130.0 million milestone payments would be subject to refund. The Company concluded that the payments that contain potentially reimbursable amounts to Baxalta are not for substantive milestones under the relevant accounting guidance, since the guidance does not allow the substantive milestone components of a payment to be bifurcated from non-substantive milestone components. Therefore, the Company will record the portion of the contingent payment that contains the claw-back feature as a liability for the potential reimbursement of such funds to Baxalta until the earlier to occur of: (1) expiration of the license agreement pursuant to its terms in August 2023, (2) the earlier termination of the license agreement, or (3) the determination, pursuant to the terms of the license agreement, of the third party to commercialize CHS-0214 in the U.S. This liability is included in the contingent liability to collaborator on the condensed consolidated balance sheets. The portion of the milestone payment that does not contain the claw-back feature will be recorded as deferred revenue and recognized as license revenue on a straight-line basis over the remaining estimated performance period. The Company determined that there is no other method that is more appropriate than the straight-line method of revenue recognition for this agreement given there is no discernable pattern of performance under the arrangement.

Pursuant to the Second Amendment, the Company received a total of $100.0 million in milestone payments in 2015 which are subject to the 50% claw-back feature. Therefore, the Company recorded $38.6 million as contingent liability to collaborator and $61.4 million as deferred revenue which is being amortized over the remaining estimated performance period using the straight line method.

As of March 31, 2016, $80.0 million of revenue was deferred under the arrangements with Baxalta, of which $48.0 million was included in current liabilities and $32.0 million was included in non-current liabilities in the condensed consolidated balance sheet. As of March 31, 2016, $66.3 million was recorded as contingent liability to collaborator due to the potential refund of such amount to Baxalta in the future.

As of December 31, 2015, $92.0 million of revenue was deferred under the arrangements with Baxalta, of which $48.0 million was included in current liabilities and $44.0 million was included in non-current liabilities in the condensed consolidated balance sheet. As of December 31, 2015, $66.3 million was recorded as contingent liability to collaborator in the condensed consolidated balance sheet due to the potential refund to Baxalta.

Convertible Notes

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Convertible Notes

6.	Convertible Notes

On February 29, 2016, the Company issued and sold $100.0 million aggregate principal amount of its 8.2% Convertible Senior Notes (the “Convertible Notes”) and received total net proceeds of approximately $99.2 million, after deducting issuance costs of $0.8 million. The Convertible Notes constitute general, senior unsubordinated obligations of the Company and are guaranteed by certain subsidiaries of the Company. The Convertible Notes bear interest at a fixed coupon rate of 8.2% per annum payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year, which commenced on March 31, 2016, and mature on March 31, 2022, unless earlier converted, redeemed or repurchased. If the Company fails to satisfy certain registration or reporting requirements, then additional interest will accrue on the Convertible Notes at a rate of up to 0.50% per annum in the aggregate. The Convertible Notes also bear a premium of 9% of their principal amount, which is payable when the Convertible Notes mature or are repurchased or redeemed by the Company.

The Convertible Notes were issued to Healthcare Royalty Partners III, L.P., for $75.0 million in aggregate principal amount, and to three related party investors, KKR Biosimilar L.P., MX II Associates LLC, and KMG Capital Partners, LLC, for $20.0 million, $4.0 million, and $1.0 million, respectively, in aggregate principal amount.

The Convertible Notes are convertible at the option of the holder at any time prior to the close of business on the business day immediately preceding March 31, 2022 at the initial conversion rate of 44.7387 shares of common stock per $1,000 principal amount of Convertible Notes, which is equivalent to an initial conversion price of approximately $22.35 per share, and is subject to adjustment in certain events. Upon conversion of the Convertible Notes by a holder, the holder will receive shares of the Company’s common stock together, if applicable, with cash in lieu of any fractional share.

The Convertible Notes are redeemable in whole, and not in part, at the Company’s option on or after March 31, 2020, if the last reported sale price per share of common stock exceeds 160% of the conversion price on 20 or more trading days during the 30 consecutive trading days preceding the date on which the Company sends notice of such redemption to the holders of the Convertible Notes. At maturity or redemption, if not earlier converted, the Company will pay 109% of the principal amount of the Convertible Notes maturing or being redeemed, together with accrued and unpaid interest, in cash.

The Convertible Notes contain customary events of default (as defined in the Convertible Note purchase agreement), the occurrence of which could result in the acceleration of all amounts due under the Convertible Notes. These events of default include, among others, certain failures to pay amounts due on the Convertible Notes, to deliver the consideration due upon conversion or to settle uninsured judgments, decrees or orders exceeding $10.0 million, and certain defaults on other indebtedness for money borrowed of at least $10.0 million, insolvency-related events and breaches of representations, subject, in some cases, to a cure period. The Convertible Notes also contain covenants restricting the Company’s ability to incur additional indebtedness for borrowed money or convertible preferred stock and to pay dividends or make distributions on the Company’s equity interests, subject to certain exceptions. As of March 31, 2016, the Company was in full compliance with these covenants and there were no events of default under the Convertible Notes.

The Convertible Notes are accounted for in accordance with ASC Subtopic 470-20, Debt with Conversion and Other Options. Pursuant to ASC Subtopic 470-20, the Company evaluated the features embedded in the Convertible Notes and concluded that the embedded features are not required to be bifurcated and accounted for separately from the host debt instrument.

The Company granted the holders of the Convertible Notes certain registration rights requiring the Company to register, under the Securities Act of 1933, as amended, the resale of the shares of common stock issuable upon conversion or settlement of the Convertible Notes.

The following table summarizes information about the components of the Convertible Notes as of March 31, 2016 (in thousands):

	March 31,
	2016
Principal amount of the Convertible Notes	$	81,750
Unamortized debt discount and debt issuance costs		(7,258	)
Convertible Notes	$	74,492

Principal amount of the Convertible Notes - related parties	$	27,250
Unamortized debt discount and debt issuance costs - related parties		(2,419	)
Convertible Notes - related parties	$	24,831
Total Convertible Notes	$	99,323

The carrying value of the Company’s Convertible Notes approximates fair value at March 31, 2016.

The following table presents the components of interest expense for the three months ended March 31, 2016 (in thousands):

	Three Months Ended
	March 31,
	2016
Stated coupon interest	$	547
Accretion of debt discount and debt issuance costs		80
Interest expense	$	627
Stated coupon interest - related parties	$	182
Accretion of debt discount and debt issuance costs - related parties		27
Interest expense - related parties	$	209
Total interest expense	$	836

The remaining unamortized debt discount and debt offering costs related to the Company’s Convertible Notes of approximately $9.7 million as of March 31, 2016, will be amortized using the effective interest rate over the remaining term of the Convertible Notes of 6.0 years. The annual effective interest rate is 9.48% for the Convertible Notes.

Future payments on the Convertible Notes as of March 31, 2016 are as follows (in thousands):

Year ending December 31,
Remainder of 2016	$	6,150
2017		8,200
2018		8,200
2019		8,200
2020		8,200
2021 and thereafter		119,250
Total minimum payments		158,200
Less amount representing interest		(49,200	)
Convertible Notes, gross		109,000
Less debt discount and debt issuance costs on Convertible Notes		(9,677	)
Net carrying amount of Convertible Notes	$	99,323

Commitments and Contingencies

3 Months Ended

Mar. 31, 2016

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

7.	Commitments and Contingencies

Purchase Commitments

The Company enters into contracts in the normal course of business with contract research organizations for preclinical studies and clinical trials and contract manufacturing organizations (“CMOs”) for the manufacture of clinical trial materials. As of March 31, 2016, the Company had a commitment of $9.8 million with CMOs for the manufacture of clinical trial material due within a year.

Guarantees and Indemnifications

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company would assess the likelihood of any adverse judgments or related claims, as well as ranges of probable losses. In the cases where the Company believes that a reasonably possible or probable loss exists, it will disclose the facts and circumstances of the claims, including an estimate range, if possible. The Company is subject to one claim that is probable or reasonably possible and consequently recorded a related liability of $50,000 in 2015.

Stock-Based Compensation

3 Months Ended

Mar. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

8.	Stock-Based Compensation

During 2010 and 2011, the Company issued shares of restricted common stock to its founders under our founders’ shares agreements (such shares, the “Founders’ Shares”). As of March 31, 2016, all shares were fully vested and there were no shares subject to repurchase. The Company recognized stock-based compensation expense within its condensed consolidated statement of operations of $0 and $6,000 for the three months ended March 31, 2016 and 2015, respectively, related to shares of common stock granted pursuant to the Founders’ Shares agreements.

The stock-based compensation expense recorded related to options granted to employees and nonemployees was as follows (in thousands):

	Three Months Ended
	March 31,
	2016		2015
Research and development	$	2,520	$	1,176
General and administrative		2,798		1,000
	$	5,318	$	2,176

Net Loss Per Share Attributable to Coherus

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Net Loss Per Share Attributable to Coherus

9.	Net Loss Per Share Attributable to Coherus

The following table sets forth the computation of the basic and diluted net loss per share attributable to Coherus (in thousands, except share and per share data):

	Three Months Ended
	March 31,
	2016			2015
Numerator:
Net loss attributable to Coherus	$	(65,388	)	$	(40,725	)
Denominator:
Weighted-average common shares outstanding		39,095,975			33,390,930
Less: weighted-average unvested common shares subject to repurchase (1)		—			(13,632	)
Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted		39,095,975			33,377,298
Net loss per share attributable to Coherus, basic and diluted	$	(1.67	)	$	(1.22	)

(1)	Shares were excluded as such shares represent restricted common stock granted pursuant to the Founders’ Shares agreements which vest contingently upon the holders’ continued services to the Company.

The following outstanding potentially dilutive securities consisting of stock options and the shares issuable upon conversion of the Convertible Notes are considered to be potential shares but are excluded from the calculation of diluted net loss per share because their effect would be antidilutive:

	March 31,
	2016		2015
Stock options outstanding		8,110,487		6,154,625
Shares issuable upon conversion of Convertible Notes		4,473,871		—
Total		12,584,358		6,154,625

Related Party Transactions

3 Months Ended

Mar. 31, 2016

Related Party Transactions

10.	Related Party Transactions

Transactions Associated with Medpace Agreement

One member of the Company’s board of directors is also the chief executive officer of Medpace. As such, Medpace was deemed to be a related party. As March 31, 2016, the Company had $6.9 million in prepaid assets (prepaid clinical, material, manufacturing and other–related parties), $3.5 million in accounts payable–related parties, and $6.3 million in accrued and other liabilities (accrued clinical, manufacturing and other–related parties), all reflected on the Company’s condensed consolidated balance sheet associated with Medpace. As of December 31, 2015, the Company had $10.9 million in prepaid assets (prepaid clinical, material, manufacturing and other–related parties), $3.5 million in accounts payable–related parties, and $6.1 million in accrued and other liabilities (accrued clinical, manufacturing and other–related parties), all reflected on the Company’s condensed consolidated balance sheet associated with Medpace. The Company recognized $13.1 million and $11.5 million during the three months ended March 31, 2016 and 2015, respectively, for services rendered by Medpace within research and development expense in the condensed consolidated statements of operations.

Recruiting Services

One member of the Company’s board of directors was the chief executive officer of a company that provided recruiting services to the Company. As of March 31, 2016, the Company had $22,000 in accounts payable-related parties on the Company’s condensed consolidated balance sheet. As of December 31, 2015, there were no such balances in the Company’s condensed consolidated balance sheet. The Company recorded in research and development expense in its condensed consolidated statements of operations, $131,000 and $0 for the three months ended March 31, 2016 and 2015, respectively, for services rendered by the recruiting company. The Company recorded in general and administrative expense in its condensed consolidated statements of operations, $0 and $66,000 for the three months ended March 31, 2016 and 2015, respectively, for services rendered by the recruiting company.

Convertible Notes

In February 2016, the Company issued Convertible Notes to certain related parties (some companies affiliated with members of the Company’s board of directors), for an aggregate principal amount of $25.0 million (see Note 6 for related party disclosure).

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Subsequent Event

3 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

Subsequent Event

11.	Subsequent Event

On May 6, 2016, the Company received a $30.0 million milestone payment from Baxalta, pursuant to the Second Amendment. The milestone payment relates to the completion of the last patient follow-up visit in both Phase 3 clinical studies for CHS-0214, the Company’s etanercept biosimilar candidate.

Basis of Presentation and Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Unaudited Condensed Consolidated Financial Statements

Use of Estimates

Foreign Currency

Segment Reporting and Customer Concentration

The following table summarizes revenue by geographic region (in thousands):

	Three Months Ended
	March 31,
	2016		2015
United States	$	12,005	$	5,313
Rest of world		354		497
Total revenue	$	12,359	$	5,810

Customers whose collaboration and license revenue accounted for 10% or more of total revenues were as follows:

	Three Months Ended
	March 31,
	2016			2015
Baxalta		97	%		91	%

Revenue Recognition

Comprehensive Loss

Net Loss per Share Attributable to Coherus

Recent Accounting Pronouncements

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Summary of Revenue by Geographical Region

The following table summarizes revenue by geographic region (in thousands):

	Three Months Ended
	March 31,
	2016		2015
United States	$	12,005	$	5,313
Rest of world		354		497
Total revenue	$	12,359	$	5,810

Summary of Customers Revenue Accounted for 10% or More of Total Revenue

Customers whose collaboration and license revenue accounted for 10% or more of total revenues were as follows:

	Three Months Ended
	March 31,
	2016			2015
Baxalta		97	%		91	%

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2016

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Financial Assets and Liabilities Measured on a Recurring Basis

Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements are as follows (in thousands):

	Fair Value Measurements
	March 31, 2016
	Total		Level 1		Level 2		Level 3
Assets:
Money market funds	$	179,403	$	179,403	$	—	$	—
Restricted cash (money market funds)		845		845		—		—
Total financial assets	$	180,248	$	180,248	$	—	$	—
Liabilities:
Contingent consideration	$	1,435	$	—	$	—	$	1,435

	Fair Value Measurements
	December 31, 2015
	Total		Level 1		Level 2		Level 3
Assets:
Money market funds	$	157,784	$	157,784	$	—	$	—
Restricted cash (money market funds)		845		845		—		—
Total financial assets	$	158,629	$	158,629	$	—	$	—
Liabilities:
Contingent consideration	$	1,245	$	—	$	—	$	1,245

Contingent Consideration | Fair Value Measurements Recurring Basis

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Financial Assets and Liabilities Measured on a Recurring Basis

The following table sets forth a summary of changes in the estimated fair value of the contingent consideration (in thousands):

Balance as of December 31, 2015	$	1,245
Change in fair value of the contingent consideration liability		190
Balance as of March 31, 2016	$	1,435

Balance Sheet Components (Tables)

3 Months Ended

Mar. 31, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Prepaid Assets

Prepaid assets are as follows (in thousands):

	March 31,		December 31,
	2016		2015
Prepaid clinical, material, manufacturing and other - related parties (see Note 10)	$	6,891	$	10,901
Prepaid clinical, material and manufacturing		16,320		21,191
Prepaid other		2,774		2,651
Prepaid assets	$	25,985	$	34,743

Schedule of Property and Equipment, Net

Property and equipment, net are as follows (in thousands):

	March 31,			December 31,
	2016			2015
Machinery and equipment	$	8,159		$	7,809
Computer equipment and software		1,374			1,276
Furniture and fixtures		578			596
Leasehold improvements		4,050			4,343
Total property and equipment		14,161			14,024
Accumulated depreciation and amortization		(3,865	)		(3,520	)
Property and equipment, net	$	10,296		$	10,504

Schedule of Accrued Liabilities

Accrued liabilities are as follows (in thousands):

	March 31,		December 31,
	2016		2015
Accrued clinical, manufacturing and other - related parties (See Note 10)	$	6,256	$	6,122
Accrued clinical and manufacturing		8,318		11,681
Accrued compensation		2,664		4,666
Accrued professional and consulting fees		697		446
Accrued other		1,344		1,218
Accrued liabilities	$	19,279	$	24,133

Collaboration and License Agreements (Tables)

3 Months Ended

Mar. 31, 2016

Collaboration And License Agreements [Abstract]

Schedule of Revenue Related to Collaboration and License Agreements

The Company recognized revenue related to the collaboration and license agreements for the periods presented as follows (in thousands):

	Three Months Ended
	March 31,
	2016		2015
Baxalta	$	12,005	$	5,313
Daiichi Sankyo		354		497
Total collaboration and license revenue	$	12,359	$	5,810

Convertible Notes (Tables)

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Components of Convertible Notes

The following table summarizes information about the components of the Convertible Notes as of March 31, 2016 (in thousands):

	March 31,
	2016
Principal amount of the Convertible Notes	$	81,750
Unamortized debt discount and debt issuance costs		(7,258	)
Convertible Notes	$	74,492

Principal amount of the Convertible Notes - related parties	$	27,250
Unamortized debt discount and debt issuance costs - related parties		(2,419	)
Convertible Notes - related parties	$	24,831
Total Convertible Notes	$	99,323

Components of Interest Expense

The following table presents the components of interest expense for the three months ended March 31, 2016 (in thousands):

	Three Months Ended
	March 31,
	2016
Stated coupon interest	$	547
Accretion of debt discount and debt issuance costs		80
Interest expense	$	627
Stated coupon interest - related parties	$	182
Accretion of debt discount and debt issuance costs - related parties		27
Interest expense - related parties	$	209
Total interest expense	$	836

Schedule of Future Payments on the Convertible Notes

Future payments on the Convertible Notes as of March 31, 2016 are as follows (in thousands):

Year ending December 31,
Remainder of 2016	$	6,150
2017		8,200
2018		8,200
2019		8,200
2020		8,200
2021 and thereafter		119,250
Total minimum payments		158,200
Less amount representing interest		(49,200	)
Convertible Notes, gross		109,000
Less debt discount and debt issuance costs on Convertible Notes		(9,677	)
Net carrying amount of Convertible Notes	$	99,323

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2016

Employees And Nonemployees Stock Option

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Schedule of Stock-Based Compensation Expense

The stock-based compensation expense recorded related to options granted to employees and nonemployees was as follows (in thousands):

	Three Months Ended
	March 31,
	2016		2015
Research and development	$	2,520	$	1,176
General and administrative		2,798		1,000
	$	5,318	$	2,176

Net Loss Per Share Attributable to Coherus (Tables)

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Loss Per Share Attributable to Coherus

The following table sets forth the computation of the basic and diluted net loss per share attributable to Coherus (in thousands, except share and per share data):

	Three Months Ended
	March 31,
	2016			2015
Numerator:
Net loss attributable to Coherus	$	(65,388	)	$	(40,725	)
Denominator:
Weighted-average common shares outstanding		39,095,975			33,390,930
Less: weighted-average unvested common shares subject to repurchase (1)		—			(13,632	)
Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted		39,095,975			33,377,298
Net loss per share attributable to Coherus, basic and diluted	$	(1.67	)	$	(1.22	)

(1)	Shares were excluded as such shares represent restricted common stock granted pursuant to the Founders’ Shares agreements which vest contingently upon the holders’ continued services to the Company.

Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share

	March 31,
	2016		2015
Stock options outstanding		8,110,487		6,154,625
Shares issuable upon conversion of Convertible Notes		4,473,871		—
Total		12,584,358		6,154,625

Organization and Operations - Additional Information (Details) $ in Thousands		3 Months Ended
	Feb. 29, 2016 USD ($)	Mar. 31, 2016 USD ($) Segments	Dec. 31, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Organization And Operations [Line Items]
Number of operating segments \| Segments		1
Accumulated deficit		$ 475,373	$ 409,985
Cash and cash equivalents		$ 179,558	$ 158,226	$ 115,136	$ 150,392
8.2% Senior Convertible Notes Due 2022
Organization And Operations [Line Items]
Aggregate principal amount	$ 100,000
Convertible notes, interest rate	8.20%
Debt instrument maturity date	Mar. 31, 2022

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended
	Mar. 31, 2016 USD ($) Segments	Mar. 31, 2015 USD ($)
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Foreign exchange loss \| $	$ 264,000
Foreign exchange gain \| $		$ 91,000
Number of reportable segment \| Segments	1
Number of operating segments \| Segments	1
RUSSIA \| Coherus Intermediate Corp, InteKrin Therapeutics, Inc.
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Controlling interest, ownership percentage by parent	82.50%

Basis of Presentation and Summary of Significant Accounting Policies - Summary of Revenue by Geographical Region (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenue	$ 12,359	$ 5,810
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenue	12,005	5,313
Rest of World
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenue	$ 354	$ 497

Basis of Presentation and Summary of Significant Accounting Policies - Summary of Customers Revenue Accounted for 10% or More of Total Revenue (Details)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Collaboration and License Revenue \| Customer Concentration Risk \| Baxalta
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Percentage of total revenues by single customer	97.00%	91.00%

Fair Value Measurements - Additional Information (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Mar. 06, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfers from Level 1 to Level 3	$ 0		$ 0
Transfers from Level 3 to Level 1	0		$ 0
Remeasurement of contingent consideration	190,000	$ 4,214,000
Other Expense, Net
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Remeasurement of contingent consideration	$ 190,000	$ 75,000
InteKrin Therapeutics Inc
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Additional fair value of earn-out payment to other expense				$ 4,100,000
Fair Value Measurements Recurring Basis \| Level 3 \| Contingent Consideration
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Discount rate	25.00%
Counterparty credit risk given the cash payment	7.00%
Fair Value Measurements Recurring Basis \| Money Market Funds \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Unrealized gains and losses on investments	$ 0

Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value Measurements Recurring Basis - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 180,248	$ 158,629
Contingent Consideration
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities	1,435	1,245
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	180,248	158,629
Level 3 \| Contingent Consideration
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities	1,435	1,245
Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	179,403	157,784
Money Market Funds \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	179,403	157,784
Restricted Cash (Money Market Funds)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	845	845
Restricted Cash (Money Market Funds) \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 845	$ 845

Fair Value Measurements - Summary of Changes in the Estimated Fair Value of Contingent Consideration (Details) - Contingent Consideration $ in Thousands	3 Months Ended
	Mar. 31, 2016 USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 1,245
Change in fair value of the contingent consideration liability	190
Ending balance	$ 1,435

Balance Sheet Components - Schedule of Prepaid Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Schedule Of Prepaid Assets [Line Items]
Prepaid assets	$ 25,985	$ 34,743
Clinical Material Manufacturing And Other Related Parties
Schedule Of Prepaid Assets [Line Items]
Prepaid assets	6,891	10,901
Prepaid Clinical, Material and Manufacturing
Schedule Of Prepaid Assets [Line Items]
Prepaid assets	16,320	21,191
Prepaid Other
Schedule Of Prepaid Assets [Line Items]
Prepaid assets	$ 2,774	$ 2,651

Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Total property and equipment	$ 14,161	$ 14,024
Accumulated depreciation and amortization	(3,865)	(3,520)
Property and equipment, net	10,296	10,504
Machinery and Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	8,159	7,809
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Total property and equipment	1,374	1,276
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Total property and equipment	578	596
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment	$ 4,050	$ 4,343

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Property Plant And Equipment [Abstract]
Depreciation and amortization	$ 717	$ 232

Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Accrued clinical, manufacturing and other - related parties	$ 6,256	$ 6,122
Accrued clinical and manufacturing	8,318	11,681
Accrued compensation	2,664	4,666
Accrued professional and consulting fees	697	446
Accrued other	1,344	1,218
Accrued liabilities	$ 19,279	$ 24,133

Collaboration and License Agreements - Schedule of Revenue Related to Collaboration and License Agreements (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Aug. 31, 2013	Mar. 31, 2016	Mar. 31, 2015
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration and license revenue		$ 12,359	$ 5,810
Baxalta License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration and license revenue	$ 30,000	12,005	5,313
Daiichi Sankyo - Related Party
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration and license revenue		$ 354	$ 497

Collaboration and License Agreements - Additional Information (Details) - USD ($)	1 Months Ended				3 Months Ended		12 Months Ended
	Jun. 30, 2015	Feb. 28, 2014	Jan. 31, 2014	Aug. 31, 2013	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Apr. 30, 2015	Jan. 31, 2012
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue, current					$ 49,633,000		$ 49,621,000
Deferred revenue, non-current					32,973,000		45,338,000
Collaboration and license revenue					12,359,000	$ 5,810,000
Contingent liability to collaborator					66,255,000		66,255,000
Baxalta License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue					80,000,000		92,000,000
Deferred revenue, current					48,000,000		48,000,000
Deferred revenue, non-current					32,000,000		44,000,000
Collaboration and license revenue				$ 30,000,000	12,005,000	5,313,000
Contingent payment receivable				120,000,000					$ 130,000,000
Increase in license agreement non-substantive contingent milestone receivable		$ 5,300,000
Contingent payment development related expenses				$ 71,300,000
Contingent payments refundable, percentage				50.00%
Contingent liability to collaborator					$ 66,300,000		66,300,000
Baxalta License Agreement \| Clinical Development Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment received								$ 85,300,000
Baxalta License Agreement \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent payment receivable		221,300,000		$ 216,000,000
Baxalta License Agreement \| Maximum \| Clinical Development Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent payment receivable		101,300,000		96,000,000
Baxalta License Agreement \| Maximum \| Regulatory Milestone Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent payment receivable		$ 120,000,000		$ 120,000,000
Baxalta Second Amendment
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue							61,400,000
Milestone payment received							$ 100,000,000
Contingent payments refundable, percentage							50.00%
Expiration of license agreement					2023-08
Contingent liability to collaborator							$ 38,600,000
Daiichi Sankyo - Related Party
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue					$ 2,400,000		2,800,000			$ 10,000,000
Minimum percentage of clinical trial cost	20.00%		20.00%
Deferred revenue, current					1,400,000		1,500,000
Deferred revenue, non-current					1,000,000		$ 1,300,000
Research and development					1,100,000	1,400,000
Collaboration and license revenue					$ 354,000	$ 497,000

Convertible Notes - Additional Information (Details)		3 Months Ended
Convertible Notes - Additional Information (Details)	Feb. 29, 2016 USD ($) d $ / shares shares	Mar. 31, 2016 USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of convertible notes		$ 75,000,000
KKR Member
Debt Instrument [Line Items]
Aggregate principal amount	$ 20,000,000
MX II Member
Debt Instrument [Line Items]
Aggregate principal amount	4,000,000
KMGCP Member
Debt Instrument [Line Items]
Aggregate principal amount	1,000,000
HRP III Member
Debt Instrument [Line Items]
Aggregate principal amount	75,000,000
8.2% Senior Convertible Notes Due 2022
Debt Instrument [Line Items]
Aggregate principal amount	$ 100,000,000
Convertible notes, interest rate	8.20%
Proceeds from issuance of convertible notes	$ 99,200,000
Convertible notes, Issuance Cost	$ 800,000
Convertible notes, interest rate description		The Convertible Notes bear interest at a fixed coupon rate of 8.2% per annum payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year, which commenced on March 31, 2016
Debt instrument maturity date	Mar. 31, 2022
Convertible notes, premium percentage	9.00%
Common shares at conversion \| shares	44.7387
Conversion price per common share \| $ / shares	$ 22.35
Principal amount of notes converted into shares	$ 1,000
Percentage of applicable conversion price	160.00%
Convertible trading days \| d	20
Convertible consecutive trading days	30 days
Percentage to pay in cash of the par value of notes	109.00%
Minimum order amount to be settled		$ 10,000,000
Minimum borrowings for indebtedness defaulters		$ 10,000,000
Convertible notes, covenant compliance		As of March 31, 2016, the Company was in full compliance with these covenants and there were no events of default under the Convertible Notes.
Unamortized debt discount and debt issuance costs on Convertible Notes		$ 9,677,000
Amortized effective interest rate convertible notes period		6 years
Convertible notes, effective interest rate		9.48%
8.2% Senior Convertible Notes Due 2022 \| Maximum
Debt Instrument [Line Items]
Additional interest to be accrued upon failure of registration or reporting requirements	0.50%

Convertible Notes - Components of Convertible Notes (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Feb. 29, 2016
Debt Instrument [Line Items]
Convertible Notes	$ 74,492
Convertible Notes - related parties	24,831
8.2% Senior Convertible Notes Due 2022
Debt Instrument [Line Items]
Principal amount of the Convertible Notes		$ 100,000
Unamortized debt discount and debt issuance costs	(9,677)
Total Convertible Notes	99,323
8.2% Senior Convertible Notes Due 2022 \| Related Party Debt
Debt Instrument [Line Items]
Principal amount of the Convertible Notes	27,250
Unamortized debt discount and debt issuance costs	(2,419)
Convertible Notes - related parties	24,831
8.2% Senior Convertible Notes Due 2022 \| Parent Company
Debt Instrument [Line Items]
Principal amount of the Convertible Notes	81,750
Unamortized debt discount and debt issuance costs	(7,258)
Convertible Notes	$ 74,492

Convertible Notes - Components of Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument [Line Items]
Accretion of debt discount and debt issuance costs	$ 107	$ (22)
Interest expense	209	$ 0
Total interest expense	837
8.2% Senior Convertible Notes Due 2022
Debt Instrument [Line Items]
Total interest expense	836
8.2% Senior Convertible Notes Due 2022 \| Related Party Debt
Debt Instrument [Line Items]
Stated coupon interest	182
Accretion of debt discount and debt issuance costs	27
Interest expense	209
8.2% Senior Convertible Notes Due 2022 \| Parent Company
Debt Instrument [Line Items]
Stated coupon interest	547
Accretion of debt discount and debt issuance costs	80
Interest expense	$ 627

Convertible Notes - Schedule of Future Payments on the Convertible Notes (Details) - 8.2% Senior Convertible Notes Due 2022 $ in Thousands	Mar. 31, 2016 USD ($)
Debt Instrument [Line Items]
Remainder of 2016	$ 6,150
2017	8,200
2018	8,200
2019	8,200
2020	8,200
2021 and thereafter	119,250
Total minimum payments	158,200
Less amount representing interest	(49,200)
Convertible Notes, gross	109,000
Less debt discount and debt issuance costs on Convertible Notes	(9,677)
Net carrying amount of Convertible Notes	$ 99,323

Commitments and Contingencies - Additional Information (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Liability
Purchase Commitment Excluding Longterm Commitment [Line Items]
Guarantor liability		$ 50,000
CMOs
Purchase Commitment Excluding Longterm Commitment [Line Items]
Contractual commitment due within a year	$ 9,800,000

Stock-Based Compensation - Additional Information (Details) - Restricted Common Stock (Founders Shares) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Common stock shares subject to repurchase	0
Stock-based compensation expense	$ 0	$ 6,000

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Options (Details) - Employees And Nonemployees Stock Option - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 5,318	$ 2,176
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	2,520	1,176
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 2,798	$ 1,000

Net Loss Per Share Attributable to Coherus - Computation of Basic and Diluted Net Loss Per Share Attributable to Coherus (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Numerator:
Net loss attributable to Coherus	$ (65,388)	$ (40,725)
Denominator:
Weighted-average common shares outstanding	39,095,975	33,390,930
Less: weighted-average unvested common shares subject to repurchase		(13,632)
Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted	39,095,975	33,377,298
Net loss per share attributable to Coherus, basic and diluted	$ (1.67)	$ (1.22)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Net Loss Per Share Attributable to Coherus - Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted net loss per share	12,584,358	6,154,625
Stock Options Outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted net loss per share	8,110,487	6,154,625
Shares Issuable Upon Conversion of Convertible Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted net loss per share	4,473,871

Related Party Transactions - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Feb. 29, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Prepaid assets	$ 25,985,000			$ 34,743,000
Accounts payable - related parties	3,494,000			3,548,000
Research and development expense	65,313,000	$ 36,467,000
General and administrative expenses from transactions with related party	0	66,000
Clinical Material Manufacturing And Other Related Parties
Related Party Transaction [Line Items]
Prepaid assets	6,891,000			10,901,000
Medpace Inc
Related Party Transaction [Line Items]
Accounts payable - related parties	3,500,000			3,500,000
Research and development expense	13,100,000	11,500,000
Medpace Inc \| Clinical Material Manufacturing And Other Related Parties
Related Party Transaction [Line Items]
Prepaid assets	6,900,000			10,900,000
Medpace Inc \| Accrued Clinical, Manufacturing and Other - Related Parties
Related Party Transaction [Line Items]
Accrued and other liabilities	6,300,000			6,100,000
Recruiting Services Provider
Related Party Transaction [Line Items]
Accounts payable - related parties	22,000			$ 0
Research and development expense	131,000	0
General and administrative expenses from transactions with related party	$ 0	$ 66,000
Investor \| Convertible Notes
Related Party Transaction [Line Items]
Aggregate principal amount			$ 25,000,000

Subsequent Event - Additional Information (Details) $ in Millions	May 06, 2016 USD ($)
Subsequent Event \| Baxalta License Agreement
Subsequent Event [Line Items]
Milestone payment received	$ 30.0